Tocilizumab

Overview

Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.[1][2] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

Tocilizumab was approved for medical use in the European Union in January 2009, and in the United States in January 2010.[3][4][5] WP

Uses, dosage and effects

Medical uses

In the United States, tocilizumab is indicated for the treatment of rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome, and COVID19.[6] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

In the European Union, tocilizumab is indicated for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, giant cell arteritis, cytokine release syndrome, and COVID19.[3] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

Rheumatoid arthritis

Tocilizumab is used for the treatment of moderate to severe rheumatoid arthritis, applied in combination with methotrexate, if other drugs like disease-modifying antirheumatic drugs (DMARDs) and TNF alpha blockers have proven to be ineffective or were not tolerated. It can be used as a monotherapy for patients who do not tolerate methotrexate. The drug slows down the progression of the disease and can improve physical function of patients.[7][8][9] WP

Systemic juvenile idiopathic arthritis

The treatment of systemic juvenile idiopathic arthritis is similar to rheumatoid arthritis treatment: tocilizumab is combined with methotrexate unless the latter is not tolerated. General safety and effectiveness is established for children of two years and older. In 2011, the US Food and Drug Administration (FDA) approved tocilizumab for the treatment of active systemic juvenile idiopathic arthritis.[10][11] WP

Castleman's disease

In Japan, tocilizumab is also approved for the treatment of Castleman's disease, a rare benign tumor of B cells.[7][12] WP

Giant cell arteritis

In May 2017, the FDA approved tocilizumab for giant cell arteritis.[13] WP

Cytokine release syndrome

On 30 August 2017, the FDA approved tocilizumab for cytokine release syndrome, a side effect of CAR-T cell therapies.[14] WP

COVID-19

As early as March 2020, at the height of the pandemic in Italy, Paolo Antonio Ascierto, an Italian oncologist, researched alongside his colleagues the use of the arthritis drug tocilizumab to treat severe COVID-19 pneumonia, seeing some results. The results were recognized nationally and prompted national calls for treatment protocols surrounding the research. Ascierto was heard in an official hearing at the Italian Chamber of Deputies, presenting data suggesting tocilizumab reduced COVID-19 mortality by approximately 22% in clinical use, underscoring its potential benefit. Paolo was at the center of the development of multicenter evaluations of tocilizumab against COVID-19 pneumonia during the whole year, being essential to it.[15][16][17] WP

In 2021 his research of the usage of tocilizumab against COVID-19 was evaluated by the European Medicines Agency and the European Union, where Ascierto was called to as to support such thesis.[18] WP

In June 2021, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for tocilizumab for the treatment of COVID19 in hospitalized people aged two years of age and older who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The FDA approved tocilizumab for those indications in December 2022.[19–22] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

Risks and side effects

Adverse effects

The most common adverse effects observed in clinical trials were upper respiratory tract infections (more than 10% of patients), nasopharyngitis (common cold), headache, and high blood pressure (at least 5%). The enzyme alanine transaminase was also elevated in at least 5% of patients, but in most cases without symptoms. Elevated total cholesterol levels were common. Among the less common side effects were dizziness, various infections, as well as reactions of the skin and mucosae like mild rashes, gastritis and mouth ulcer. Rare but severe reactions were gastrointestinal perforations (0.26% in six months) and anaphylaxis (0.2%).[23][24] WP

Interactions

Interactions

There are no certain interactions with other drugs. The blood plasma levels of simvastatin were reduced by 57% after a single dose of tocilizumab, but it is not known whether this is clinically relevant. A possible mechanism is that the elevated IL-6 levels of patients with rheumatoid arthritis suppress the biosynthesis of various cytochrome P450 enzymes, notably CYP1A2, CYP2C9, CYP2C19 and CYP3A4. Tocilizumab lowers IL-6 and thus normalises cytochrome levels, increasing the metabolization of simvastatin (and possibly other cytochrome metabolised drugs).[24] WP

Pharmacology

Mechanism of action

Besides other functions, interleukin 6 (IL-6) is involved in the development of immunological and inflammatory reactions. Some autoimmune diseases like rheumatoid arthritis are associated with abnormally high IL-6 levels. Tocilizumab binds soluble as well as membrane bound interleukin-6 receptors, hindering IL-6 from exerting its pro-inflammatory effects. It has been noted that the membrane bound form and soluble form of the IL-6 receptor may have different effects in the pathogenesis of rheumatoid arthritis with the soluble form being more implicated in disease progression.[24][25][26] WP

Research

Research

Tocilizumab is being studied for pulmonary arterial hypertension (PAH). Tocilizumab is under evaluation in a multicenter clinical trial (ALL-IN) for the prevention of acute cellular rejection in status post heart transplant patients. A small initial study has suggested that Tocilizumab may be helpful for difficult-to-treat depression. Larger follow-up studies are required.[27][28][29] WP

COVID-19

There is good evidence tocilizumab can help reduce the need for mechanical ventilation for people in hospital with COVID19, and some evidence it can help prevent secondary infections.[30] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

A 2021 meta-analysis of randomized controlled trials found that, while tocilizumab does not show significant benefits on survival, it could play a role in preventing progression to intensive care and mechanical ventilation.[31][32] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

Neuromyelitis optica

Early case reports suggest tocilizumab might be effective in otherwise refractory neuromyelitis optica (NMO, Devic's disease).[33–36] WP

Graves' ophthalmopathy

Two small studies found tocilizumab to be beneficial in endocrine ophthalmopathy (Graves' orbitopathy) that is refractory to corticosteroid treatment.[37][38] WP

History

History

Interleukin 6 and its receptor were discovered and cloned at Osaka University, Japan, by Tadamitsu Kishimoto in the 1980s. In 1997, Chugai Pharmaceuticals began the clinical development of tocilizumab for the treatment of rheumatoid arthritis. Clinical studies for Castleman's disease and systemic juvenile idiopathic arthritis started in 2001 and 2002, respectively. Hoffmann–La Roche co-developed the drug due to a license agreement in 2003.[2] WP

Data presented in 2008 showed the effectiveness of tocilizumab in combination therapy with methotrexate for rheumatoid arthritis treatment. In further studies, it was effective and generally well tolerated when administered either as monotherapy or in combination with conventional DMARDs in adult patients with moderate to severe rheumatoid arthritis.[39][40] WP

In June 2005, tocilizumab was approved in Japan for Castleman's disease. In January 2009, the drug was approved by the European Medicines Agency (EMA) as Roactemra for the treatment of rheumatoid arthritis under the mentioned restrictions. On 11 January 2010, it was approved by the U.S. FDA as Actemra for the same purpose. Tocilizumab was approved by Australia's Therapeutic Goods Administration on 27 May 2009 and was listed on the Pharmaceutical Benefits Scheme from August 2010. In New Zealand, tocilizumab was approved for distribution in July 2009, and Pharmac approved subsidising it with special authority restrictions in July 2013, for systemic juvenile idiopathic arthritis and in July 2014, for rheumatoid arthritis. The FDA approved tocilizumab for the treatment of systemic juvenile idiopathic arthritis for children from two years of age in April 2011, and the EMA followed in August the same year.[7][41–46] WP⚠ Wikipedia itself has flagged this text: citation needed.

Tocilizumab is marketed by Chugai in some countries, especially in Japan and other Asian countries, and jointly by Chugai and Roche (Hoffmann–La Roche's holding company) in others, for example Great Britain, France and Germany.[2] WP

Legal status

Legal status

Tocilizumab was approved for medical use in the European Union in January 2009, and in the United States in January 2010.[3][4][5] WP

Biosimilars

In September 2023, Tyenne became the first tocilizumab biosimilar authorized for medical use in the European Union, and in March 2024, became the first biosimilar with both intravenous and subcutaneous formulations to be approved in the United States.[47–50] WP

In April 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tofidence, intended for the treatment of rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA) and coronavirus disease 2019 (COVID-19). The applicant for this medicinal product is Biogen Netherlands B.V. Tofidence is a biosimilar medicinal product. Tofidence was authorized for medical use in the European Union in June 2024.[51][52][53] WP

Tyenne was approved for medical use in Canada in October 2024.[54][55] WP

In December 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Avtozma, intended for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, CAR-T cell-induced severe or life-threatening cytokine release syndrome and COVID-19. The applicant for this medicinal product is Celltrion Healthcare Hungary Kft. Avtozma is a biosimilar medicinal product.[1] WP

Tocilizumab-anoh (Avtozma) was approved for medical use in the United States in January 2025.[56][57][58] WP

Avtozma was approved for medical use in Canada in October 2025.[59] WP

COVID-19

Tocilizumab was approved for the treatment of COVID19 in the European Union in December 2021, and in the United States in December 2022.[3][22] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

In September 2021, Indian pharmaceutical firm Hetero obtained emergency use approval from the country's health authority, Drugs Controller General of India (DCGI), to produce a generic version of tocilizumab to treat COVID19 in adults.[60] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

In December 2021, tocilizumab was granted a provisional approval by the Australian regulator, Therapeutic Goods Administration, for treatment of adults.[61] WP

Tocilizumab was granted an emergency use authorization (EUA) for the treatment of COVID19 in the United States in June 2021. It was approved for the treatment of COVID19 in the European Union in December 2021, and in the United States in December 2022.[3][19–22][62][63] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Avtozma EPAR. 12 December 2024
2. Other Markus Harwart. Die Entwicklung von Tocilizumab. 2008
3. Journal / agency Roactemra EPAR. 17 September 2018
4. Journal / agency Drug Approval Package: Actemra (Tocilizumab) Injection BLA 125276. 9 March 2010
5. Journal / agency Drug Approval Package: Actemra (tocilizumab) Solution for Subcutaneous Injection NDA #125472. 17 July 2014
6. Journal / agency Actemra- tocilizumab injection, solution, concentrate Actemra- tocilizumab injection, solution Actemra ACTPen- tocilizumab injection, solution
7. Other Roactemra approved in Europe to treat patients suffering from Rheumatoid Arthritis. 21 January 2009
8. Journal / agency Assessment report for Roactemra
9. Journal / agency Fleischmann R, Burgos-Vargas R, Ambs P, Alecock E, Kremer J. LITHE: tocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis (RA) patients (Pts) at 2 yrs with increasing clinical efficacy over time. Arthritis Rheum. October 2009
10. Journal / agency De Benedetti F, Brunner H, Ruperto N, Calvo N, Cuttica I, Malattia R, Schneider R. Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis: Efficacy Data From the Placebo-Controlled 12-Week Part of the Phase 3 TENDER Trial. Arthritis & Rheumatism. 2010
11. Other FDA Approves Actemra (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA). 15 April 2011
12. Journal / agency Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Internal Medicine. 2007. doi:10.2169/internalmedicine.46.6262 · PMID 17541233
13. Other FDA Approves Actemra (tocilizumab) Subcutaneous Injection for Giant Cell Arteritis
14. Journal / agency FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. 30 August 2017
15. Other Coronavirus. Al Pascale prosegue con successo la terapia con tocilizumab. Medici chiedono un protocollo nazionale per regolamentarne uso. 20 November 2025
16. Other Scarano, Chiara Stella. Tocilizumab, semaforo verde dall’Aifa per la sperimentazione su larga scala. 18 March 2020
17. Other Scarl, Inferenze. Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. 12 May 2020
18. Other Lopes, Margherita. Covid, Ema valuta 'cura Ascierto' per forme severe. 16 August 2021
19. Journal / agency Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19. 24 June 2021
20. Journal / agency Tocilizumab Emergency Use Authorization (EUA). June 2021
21. Journal / agency Frequently Asked Questions on the Emergency Use Authorization for Actemra (tocilizumab) for Treatment of COVID-19. July 2021
22. Other FDA Approves Genentech's Actemra for the Treatment of COVID-19 in Hospitalized Adults. 21 December 2022
23. Journal / agency Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis and Rheumatism. October 2008. doi:10.1002/art.23940 · PMID 18821691
24. Other Arzneistoff-Profile. 2010
25. Journal / agency Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases. January 2010. doi:10.1136/ard.2008.105197 · PMID 19297346 · PMC3747519
26. Journal / agency Kallen KJ. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. November 2002. doi:10.1016/s0167-4889(02)00325-7 · PMID 12421676
27. Other Roche links with UK gov for ground-breaking PAH trial. 6 January 2016
28. Other ClinicalTrialsGov NCT03644667 Tocilizumab in Cardiac Transplantation
29. Other Foley ÉM, Turner N, Margelyte R, et al. Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial. JAMA Psychiatry. Published online May 20, 2026. doi:10.1001/jamapsychiatry.2026.1053
30. Journal / agency Tleyjeh IM, Kashour Z, Riaz M, Hassett L, Veiga VC, Kashour T. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Clinical Microbiology and Infection. August 2021. doi:10.1016/j.cmi.2021.04.019 · PMID 33915284 · PMC8076756
31. Journal / agency Mutua V, Henry BM, Csefalvay CV, Cheruiyot I, Vikse J, Lippi G, Bundi B, Mong'are N. Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs. Acta Bio-Medica. March 2022. doi:10.23750/abm.v93i1.12208 · PMID 35315395 · PMC8972884
32. Journal / agency Rezaei Tolzali MM, Noori M, Shokri P, Rahmani S, Khanzadeh S, Nejadghaderi SA, Fazlollahi A, Sullman MJ, Singh K, Kolahi AA, Arshi S, Safiri S. Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review. Reviews in Medical Virology. November 2022. doi:10.1002/rmv.2388 · PMID 36029180 · PMC9539231
33. Journal / agency Komai T, Shoda H, Yamaguchi K, Sakurai K, Shibuya M, Kubo K, Takahashi T, Fujio K, Yamamoto K. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report. Modern Rheumatology. 9 December 2013. doi:10.3109/14397595.2013.861333 · PMID 24313919
34. Journal / agency Kieseier BC, Stüve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurology. March 2013. doi:10.1001/jamaneurol.2013.668 · PMID 23599943
35. Journal / agency Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, Gold R. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurology. March 2013. doi:10.1001/jamaneurol.2013.1246 · PMID 23358868
36. Journal / agency Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Modern Rheumatology. July 2013. doi:10.1007/s10165-012-0715-9 · PMID 22782533 · PMC3713263
37. Journal / agency Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodríguez Alvarez FM, Castillo Laguarta JM, Del Estad Cabello A, Gessa Sorroche M, España Gregori E, Sales-Sanz M. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. American Journal of Ophthalmology. November 2018. doi:10.1016/j.ajo.2018.07.038 · PMID 30081019
38. Journal / agency Sánchez-Bilbao L, Martínez-López D, Revenga M, López-Vázquez Á, Valls-Pascual E, Atienza-Mateo B, Valls-Espinosa B, Maiz-Alonso O, Blanco A, Torre-Salaberri I, Rodríguez-Méndez V, García-Aparicio Á, Veroz-González R, Jovaní V, Peiteado D, Sánchez-Orgaz M, Tomero E, Toyos-Sáenz de Miera FJ, Pinillos V, Aurrecoechea E, Mora Á, Conesa A, Fernández-Prada M, Troyano JA, Calvo-Río V, Demetrio-Pablo R, González-Mazón Í, Hernández JL, Castañeda S, González-Gay MÁ, Blanco R. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. Journal of Clinical Medicine. August 2020. doi:10.3390/jcm9092816 · PMID 32878150 · PMC7563792
39. Other Jab hope for rheumatoid arthritis. 27 October 2008
40. Journal / agency Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009. doi:10.2165/00003495-200969050-00007 · PMID 19368420
41. Other Roche: FDA Approves Actemra For Rheumatoid Arthritis. 11 January 2010
42. Other Australian Drug Evaluation Committee 263rd meeting resolutions. 27 May 2009
43. Other Anakinra (Kineret) to be deleted from the PBS. 1 August 2010
44. Journal / agency Richards M. Consent to the Distribution of New Medicines. New Zealand Gazette. 20 July 2009
45. Other Approval of proposal involving pegfilgrastim and tocilizumab. 24 May 2013
46. Other Decision to widen access to tocilizumab (Actemra) for rheumatoid arthritis in patients who are unable to be treated with methotrexate. 14 May 2014
47. Journal / agency Tyenne EPAR. 2 October 2023
48. Other Tyenne Biosimilar: EC Approval. 19 September 2023
49. Journal / agency Archived copy
50. Other Tyenne marks the third biosimilar to receive FDA approval. 7 March 2024
51. Journal / agency Tofidence EPAR. 25 April 2024
52. Journal / agency Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024. 26 April 2024
53. Other Tofidence PI. 21 June 2024
54. Other Regulatory Decision Summary for Tyenne. 11 October 2024
55. Other Summary Basis of Decision for Tyenne. 1 September 2012
56. Journal / agency Drug Approval Package: Avtozma
57. Other U.S. FDA approves Celltrion's Avtozma (tocilizumab-anoh), a biosimilar to Actemra. 11 February 2025
58. Other Celltrion launches Avtozma (tocilizumab-anoh) intravenous (IV) formulation in the United States. 2 October 2025
59. Other Summary Basis of Decision for Avtozma. 16 December 2025
60. Other Hetero obtains DCGI approval to produce Roche's Covid-19 drug in India. 7 September 2021
61. Other TGA Provisional Approval of Roche Products Pty Ltd COVID-19 treatment, tocilizumab (ACTEMRA). 1 December 2021
62. Journal / agency EMA recommends approval for use of Roactemra in adults with severe COVID-19. 6 December 2021
63. Other Roactemra. 19 January 2009

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.